Editor's Note: Green and red arrows refer to intraday stock price movement.NEW YORK ( TheStreet) -- CHANGE IN RATINGS Arch Coal ( ACI) downgraded at Jefferies from Buy to Hold, Jefferies said. Valuation call. Advanced Micro ( AMD) downgraded at Wells to Underperform, Wells Fargo said. Company could continue to lose market share and the departure of the CEO could hang over the stock. AMR ( AMR) downgraded at UBS from Buy to Neutral, UBS said. $10 price target. Dispute with online travel agents could actually hurt near-term earnings. Acuity Brands ( AYI) downgraded at Oppenheimer from Outperform to Perform, Oppenheimer said. Valuation call. CIT Group ( CIT) rated new Buy at Citigroup. $57 price target. Stock is near book value and the company's turnaround is gaining momentum. CIT Group ( CIT) rated new Equal-weight at Morgan Stanley. $48 price target. Company still faces funding constraints. Diamond Offshore ( DO) upgraded at Jefferies from Underperform to Hold, Jefferies said. Company should see better mid-water and deepwater returns. Energy Conversion ( ENER) devices downgraded at Barclays to Underweight from Equal Weight. Increasing risks to sustainability of policies in key markets, along with incremental risk of pricing pressure, Barclays said. Price target cut in half to $3. Fluor ( FLR) upgraded at JP Morgan from Neutral to Overweight, JP Morgan said. $77 price target. Company should benefit from a strong commodity presence. End-market demand could also recover in other key areas. Flowserve ( FLS) rated new Neutral at UBS. $127 price target. Company faces near-term pricing concerns. FXCM Inc. ( FXCM) initiated at Barclays with an Overweight rating and $18 price target. FXCM sits in an enviable position in the retail FX industry, one that is growing faster than even the attractive rates seen in the equity e-broker world, Barclays said. GlaxoSmithKline ( GSK) upgraded at Jefferies from Hold to Buy, Jefferies said. Company is buying back stock and carrying a lot of earnings momentum into the new year. Hewlett-Packard ( HPQ) upgraded at UBS from Neutral to Buy, UBS said. $52 price target. Estimates also upped, as business spending should improve in the new year.